Compare ISPO & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ISPO | NOTV |
|---|---|---|
| Founded | 2010 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 29.9M |
| IPO Year | N/A | 1997 |
| Metric | ISPO | NOTV |
|---|---|---|
| Price | $2.82 | $0.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 30.1K | ★ 1.6M |
| Earning Date | 11-04-2025 | 12-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $247,652,000.00 | ★ $513,024,000.00 |
| Revenue This Year | N/A | $6.26 |
| Revenue Next Year | $156.55 | $45.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4.54 |
| 52 Week Low | $2.19 | $0.66 |
| 52 Week High | $7.17 | $6.48 |
| Indicator | ISPO | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 55.15 | 35.16 |
| Support Level | $2.76 | $0.79 |
| Resistance Level | $2.88 | $0.86 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 79.60 | 3.93 |
Inspirato Inc is a private, luxury hospitality club that provides its members with access to an exclusive portfolio of high-end vacation homes, luxury hotels, and curated travel experiences worldwide. The club offers personalized service, dedicated trip planning, and seamless access to exceptional properties through its innovative model designed to ensure the service, certainty and value that discerning customers demand. The Inspirato portfolio of curated luxury vacation options includes approximately 350 private luxury vacation homes and accommodations at over 220 luxury hotel and resort partners in over 180 destinations around the world.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.